Literature DB >> 11773307

Side effects of chemotherapy and combined chemohormonal therapy in women with early-stage breast cancer.

A H Partridge1, H J Burstein, E P Winer.   

Abstract

The decision to receive chemotherapy or chemohormonal therapy involves careful consideration of both the potential benefits and possible risks of therapy. There are substantial short- and long-term side effects from chemotherapy. By convention, short-term side effects include those toxic effects encountered during chemotherapy, while long-term side effects include later complications of treatment arising after the conclusion of adjuvant chemotherapy. These side effects vary, depending on the specific agents used in the adjuvant regimen as well as on the dose used and the duration of treatment. There is also considerable variability in side effect profile across individuals. This review will focus on the short- and long-term toxicity seen with the most commonly used adjuvant chemotherapy and chemohormonal therapy regimens.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11773307     DOI: 10.1093/oxfordjournals.jncimonographs.a003451

Source DB:  PubMed          Journal:  J Natl Cancer Inst Monogr        ISSN: 1052-6773


  80 in total

1.  Effect of Beta glucan on quality of life in women with breast cancer undergoing chemotherapy: a randomized double-blind placebo-controlled clinical trial.

Authors:  Alireza Ostadrahimi; Ali Esfahani; Mohammad Asghari Jafarabadi; Jamal Eivazi Ziaei; Aliakbar Movassaghpourakbari; Nazila Farrin
Journal:  Adv Pharm Bull       Date:  2014-08-25

2.  Induction of the Cdk inhibitor p21 by LY83583 inhibits tumor cell proliferation in a p53-independent manner.

Authors:  Dimitri Lodygin; Antje Menssen; Heiko Hermeking
Journal:  J Clin Invest       Date:  2002-12       Impact factor: 14.808

3.  Premature menopause in young breast cancer: effects on quality of life and treatment interventions.

Authors:  Shoshana M Rosenberg; Ann H Partridge
Journal:  J Thorac Dis       Date:  2013-06       Impact factor: 2.895

4.  Preferences for mHealth physical activity interventions during chemotherapy for breast cancer: a qualitative evaluation.

Authors:  Anne M Nielsen; Whitney A Welch; Kara L Gavin; Alison M Cottrell; Payton Solk; Emily A Torre; Danielle Blanch-Hartigan; Siobhan M Phillips
Journal:  Support Care Cancer       Date:  2019-07-31       Impact factor: 3.603

5.  Breast cancer morbidity: questionnaire survey of patients on the long term effects of disease and adjuvant therapy.

Authors:  Stefan Feiten; Jan Dünnebacke; Jochen Heymanns; Hubert Köppler; Jörg Thomalla; Christoph van Roye; Diana Wey; Rudolf Weide
Journal:  Dtsch Arztebl Int       Date:  2014-08-04       Impact factor: 5.594

6.  Lantana camara Induces Apoptosis by Bcl-2 Family and Caspases Activation.

Authors:  Eun Byeol Han; Bo Yoon Chang; Young Suk Jung; Sung Yeon Kim
Journal:  Pathol Oncol Res       Date:  2014-08-22       Impact factor: 3.201

7.  Social enrichment attenuates chemotherapy induced pro-inflammatory cytokine production and affective behavior via oxytocin signaling.

Authors:  William H Walker; O Hecmarie Meléndez-Fernández; Jordan L Pascoe; Ning Zhang; A Courtney DeVries
Journal:  Brain Behav Immun       Date:  2020-07-29       Impact factor: 7.217

8.  Phase III randomized, placebo-controlled, double-blind trial of risedronate for the prevention of bone loss in premenopausal women undergoing chemotherapy for primary breast cancer.

Authors:  Stephanie L Hines; Betty Anne Mincey; Jeff A Sloan; Sachdev P Thomas; Elaine Chottiner; Charles L Loprinzi; Mark D Carlson; Pamela J Atherton; Muhammad Salim; Edith A Perez
Journal:  J Clin Oncol       Date:  2008-12-15       Impact factor: 44.544

9.  Incidence of chemotherapy-induced amenorrhea associated with epirubicin, docetaxel and navelbine in younger breast cancer patients.

Authors:  Wen-Bin Zhou; Hong Yin; Xiao-An Liu; Xiao-Ming Zha; Lin Chen; Jun-Cheng Dai; Ai-di Tao; Ling Chen; Jing-Jing Ma; Li-Jun Ling; Shui Wang
Journal:  BMC Cancer       Date:  2010-06-11       Impact factor: 4.430

10.  Management of cardiac health in trastuzumab-treated patients with breast cancer: updated United Kingdom National Cancer Research Institute recommendations for monitoring.

Authors:  A L Jones; M Barlow; P J Barrett-Lee; P A Canney; I M Gilmour; S D Robb; C J Plummer; A M Wardley; M W Verrill
Journal:  Br J Cancer       Date:  2009-03-10       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.